The global demand for Chemotherapy-Induced Nausea and Vomiting Therapeutics Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Nausea and vomiting are common effects after chemotherapy. It remained significant and common toxicity of cancer treatment. Chemotherapy-induced nausea and vomiting (CINV) can be acute, delayed, breakthrough, anticipatory, and refractory. This can be treated using oral drugs, including 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine are other few medications used to a lesser extent.
Market Dynamics
Rising cancer prevalence, a growing number of patients undergoing chemotherapy, expanding healthcare infrastructure, and a high success rate of therapies are factors accelerating the demand for nausea and vomiting drugs induced by chemotherapy. As per World Health Organization (WHO) estimates, cancer is a leading cause of death worldwide, accounting for nearly 10 million new cases in 2020. An estimated 80% of patients with cancer undergoing chemotherapy will experience nausea and vomiting (CINV). Easing the health insurance process, expanding the number of cancer specialist hospitals worldwide, and growing life expectancy is causing a rise in the number of chemotherapies performed, propelling the market growth. However, the high cost of therapy, lack of skilled professionals, and inadequate treatment infrastructure in some parts of the region are hampering the market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chemotherapy-induced nausea and vomiting therapeutics. The growth and trends of chemotherapy-induced nausea and vomiting therapeutics industry provide a holistic approach to this study.
Market Segmentation
This section of the chemotherapy-induced nausea and vomiting therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Therapy Type
- 5-HT3 Receptor Antagonists
- NK1 Receptor Antagonists
- Corticosteroids
- Other
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Chemotherapy-Induced Nausea and Vomiting Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Share by Region (Representative Graph)
Know more about this report: Download free sample
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the chemotherapy-induced nausea and vomiting therapeutics market include GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceuticals, Heron Therapeutics, Inc., F. Hoffmann-La Roche AG, Tesaro, Inc., Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.